Fracture load of ceramic restorations after fatigue loading.

STATEMENT OF PROBLEM: A clinician must decide what ceramic coping and veneer material to prescribe based on the amount of tooth reduction possible and the desired esthetic outcome of the restoration. PURPOSE: The purpose of this in vitro study was to compare the fracture strength of monolithic and bilayered lithium disilicate (IPS e.max) and zirconia (LAVA) crowns at clinically relevant thicknesses after load cycling. MATERIAL AND METHODS: Crowns (n=8) were fabricated from 6 groups: 1.2-mm monolithic lithium disilicate, 1.5-mm monolithic lithium disilicate, 1.5-mm bilayered lithium disilicate with hand-layered veneer, 0.6 mm monolithic zirconia, 1.2-mm bilayered zirconia with hand-layered veneer, and 1.2-mm bilayered zirconia with milled veneer (dimension represents thickness at the occlusal pit). Crowns were cemented to identical milled resin dies with resin-modified glass ionomer cement. Cemented crowns were stored at 37°C for 24 hours and load cycled for 200,000 cycles at 25 N at a rate of 40 cycles/minute. The ultimate fracture load for each specimen was measured in a universal testing machine. Data were analyzed with a 1-way ANOVA and Tukey honest significant difference post hoc analysis (α=.05). RESULTS: Mean ±SD fracture load values were 1465 ±330 N for monolithic lithium disilicate (1.2-mm thickness) and 2027 ±365 N (1.5-mm thickness) and 1732 ±315 N for bilayered hand-veneered lithium disilicate (1.5-mm thickness). Fracture loads were 1669 ±311 N for monolithic zirconia crowns (0.6mm thickness), 2625 ±300 N for zirconia milled-veneered (1.2-mm thickness), and 2655 ±590N for zirconia hand-veneered crowns (1.2mm thickness). One-way ANOVA showed a statistically significant difference among the groups (P<.01). Veneered zirconia crowns showed the highest fracture strength, 1.2-mm hand veneered zirconia was similar to that of 1.5-mm monolithic zirconia, and all other groups were not statistically different. CONCLUSIONS: Crowns of 1.2-mm bilayered zirconia had higher fracture loads than 0.6-mm zirconia or 1.2-mm lithium disilicate monolithic crowns.

Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.

Unlike other antiresorptive medications, bisphosphonate molecules accumulate in the bone matrix. Previous studies of side-effects of anti-resorptive treatment focused mainly on systemic effects. We hypothesize that matrix-bound bisphosphonate molecules contribute to the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). In this study, we examined the effect of matrix-bound bisphosphonates on osteoclast differentiation in vitro using TRAP staining and resorption assay, with and without pretreatment with EDTA. We also tested the effect of zoledronate chelation on the healing of post-extraction defect in rats. Our results confirmed that bisphosphonates bind to, and can be chelated from, mineralized matrix in vitro in a dose-dependent manner. Matrix-bound bisphosphonates impaired the differentiation of osteoclasts, evidenced by TRAP activity and resorption assay. Zoledronate-treated rats that underwent bilateral dental extraction with unilateral EDTA treatment showed significant improvement in mucosal healing and micro-CT analysis on the chelated sides. The results suggest that matrix-bound bisphosphonates are accessible to osteoclasts and chelating agents and contribute to the pathogenesis of BRONJ. The use of topical chelating agents is a promising strategy for the prevention of BRONJ following dental procedures in bisphosphonate-treated patients.